Quick Answer
CytomX Therapeutics, Inc. reported R&D Expense of $68.73 million for fiscal year 2025.
CytomX Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $68.73M | -17.6% |
| 2024 | $83.38M | +7.3% |
| 2023 | $77.68M | -30.4% |
| 2022 | $111.65M | -2.2% |
| 2021 | $114.19M | +1.1% |
| 2020 | $112.94M | -14.2% |
| 2019 | $131.62M | +26.7% |
| 2018 | $103.87M | +12.6% |
| 2017 | $92.28M | +68.5% |
| 2016 | $54.76M | +93.1% |
| 2015 | $28.36M | +0.2% |
| 2014 | $28.30M | +159.9% |
| 2013 | $10.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.30M | -28.4% | +14.9% |
| June 30, 2025 | $13.32M | -47.1% | -29.4% |
| March 31, 2025 | $18.87M | -14.4% | -11.7% |
| September 30, 2024 | $21.37M | +29.9% | -15.1% |
| June 30, 2024 | $25.17M | +21.8% | +14.1% |
| March 31, 2024 | $22.05M | +4.1% | +34.1% |
| September 30, 2023 | $16.45M | -45.8% | -20.4% |
| June 30, 2023 | $20.67M | -33.7% | -2.4% |
- CytomX Therapeutics, Inc. showed a decrease of -17.6% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, CytomX Therapeutics, Inc.’s r&d expense has grown by 531.1% (from $10.89 million to $68.73 million).
- The most recent figure is from CytomX Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: